Antiparkinson agent. Idiopathic Parkinson's disease, in particular to reduce off-period in patients who previously have been treated with levodopa/decarboxylase inhibitors, or with levodopa alone and who have experienced motor fluctuations. The experience is limited with 'Sinemet CR' and 'Half Sinemet CR' in patients who have not been treated with levodopa before.
For the treatment of Parkinson's disease and syndrome.
Intec Pharma Ltd. announces top-line data from the Company's pivotal Phase III trial evaluating the safety and efficacy of the...
The FDA has approved Rytary (extended-release oral carbidopa-levodopa), from Impax Pharma, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and...